natgillin/translations-raw huggingface dataset:
Maltitol liquid (E965) Acesulfame potassium (E950) Grape flavour (contains propylene glycol) Purified water 
kalijev acesulfamat (E950) aroma grozdja (vsebuje polipropilenglikol)
In a pooled analysis, the percentage of patients who achieved 50% or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7%, 31.6% and 41.3% for patients on 1,000, 2,000 or 3,000 mg levetiracetam respectively and of 12.6% for patients on placebo. 
Kumulativna analiza je pokazala, da je bil odstotek bolnikov, ki so dosegli zmanjšanje tedenske pogostnosti napadov parcialnega izvora v primerjavi z izhodiščem za 50 % ali več, ob stabilnih odmerkih (12/14 tednov) med prejemniki 1.000 mg levetiracetama 27,7 %,
Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. 
Monoterapija za zdravljenje epileptičnih napadov parcialnega izvora s sekundarno generalizacijo ali brez nje pri bolnikih od 16. leta starosti z novoodkrito epilepsijo.
The initial therapeutic dose is 10 mg/kg twice daily. 
Začetni terapevtski odmerek je 10 mg/kg dvakrat na dan.
• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy. 
• za zdravljenje primarno generaliziranih tonično-kloničnih napadov pri odraslih in mladostnikih od 12. leta starosti, ki imajo idiopatsko generalizirano epilepsijo.
(4) Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended. 
(4) Po dializi je priporočljiv dodatni odmerek od 3,5 do 7 mg/kg (0,035 do 0,07 ml/kg).
Musculoskeletal and connective tissue disorders 
Bolezni mišično skeletnega sistema in vezivnega tkiva mišična oslabelost,
If your baby is less than 4 weeks old, talk to your doctor or pharmacist before giving them this medicine, in particular if the baby is given other medicines that contain propylene glycol or alcohol. 
Če je vaš otrok mlajši od 4 tednov, se pred dajanjem zdravila posvetujte z zdravnikom ali farmacevtom.
You should not stop your treatment without discussing this with your doctor.A risk of birth defects for your unborn child cannot be completely excluded. 
Tveganje za defekte še nerojenega otroka ni mogoče popolnoma izključiti.
As with all antiepileptic medicines, sudden discontinuation of levetiracetam should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple antiepileptic medicines AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics. 
Kot pri vseh drugih antiepileptikih se je treba nenadni prekinitvi uporabe levetiracetama izogniti, saj lahko to povzroči izbruh napadov, ki imajo lahko resne posledice za žensko in nerojenega otroka.
• suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate); 
• samomor, osebnostne motnje (vedenjske motnje), motnje mišljenja (počasno razmišljanje,
300 ml oral solution 
300 ml peroralna raztopina
for patients unable to swallow tablets or for the administration of doses below 250 mg. 
Poleg tega je treba peroralno raztopino uporabiti za uvodno zdravljenje otrok, lažjih od 25 kg, bolnikov, ki ne morejo pogoltniti tablet, in za dajanje odmerkov, manjših od 250 mg.
With continued long-term treatment, 47.4% of the patients were free of tonic-clonic seizures for at least 6 months and 31.5% were free of tonic-clonic seizures for at least 1 year. 
Med nadaljevalnim dolgoročnim zdravljenjem je bilo brez tonično-kloničnih napadov vsaj 6 mesecev 47,4 % bolnikov, vsaj 1 leto pa 31,5 % bolnikov.
The initial therapeutic dose is 7 mg/kg twice daily. 
Začetni terapevtski odmerek je 7 mg/kg dvakrat na dan.
With continued long-term treatment, 8.6% of the patients were seizure-free for at least 6 months and 7.8 % were seizure-free for at least 1 year. 
Med nadaljevanjem dolgotrajnega zdravljenja je bilo 8,6 % bolnikov brez napadov vsaj 6 mesecev, 7,8 % pa jih je bilo brez napadov vsaj 1 leto.
A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. 
(starih od 4 do 17 let) je potrdila, da dopolnilno zdravljenje s peroralnim levetiracetamom ni vplivalo na koncentracijo sočasno uporabljenega karbamazepina in valproata v serumu v stanju dinamičnega ravnovesja.
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinylestradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. 
(etinilestradiola in levonorgestrela); endokrini parametri (luteinizirajoči hormon in progesteron) se niso spremenili.
(5) Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended. 
(5) Po dializi je priporočljiv dodatni odmerek od 5 do 10 mg/kg (0,05 do 0,10 ml/kg).
Turn the bottle upside down with the syringe still in place (Figure 4). 
Obrnite stekleničko na glavo; brizga naj medtem ostane nameščena (slika 4).
Rare disorders headache disorder, dizziness, lethargy, tremor impairment, coordination abnormal/ataxia, paraesthesia, disturbance in attention dyskinesia, hyperkinesia, gait disturbance, encephalopathy 
letargija, tremor koordinacija/ataksija, parestezija, motnje pozornosti hiperkinezija, motnje hoje, encefalopatija
180 mg (1.8 ml) twice daily 
180 mg (1,8 ml) dvakrat na dan
Adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy. 
Dopolnilno zdravljenje primarno generaliziranih tonično-kloničnih napadov pri odraslih in mladostnikih od 12. leta starosti z idiopatsko generalizirano epilepsijo.
Measure the appropriate dosage using the 10 ml syringe included in the package for patients of 4 years and above. 
Ustrezen odmerek izmerite z uporabo 10-mililitrske brizge, vključene v pakiranje za bolnike, stare
Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme 
Bolezni kože in podkožja izpuščaj alopecija, ekcem, pruritus toksična epidermalna nekroliza, StevensJohnsonov sindrom, multiformni eritem
Quincke's oedema [swelling of the face, lips, tongue and throat]); 
Quinckejev edem [otekanje obraza, ustnic, jezika in žrela]) • znižana koncentracija natrija v krvi
Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours. 
Otroci (4 do 12 let) Po uporabi enega peroralnega odmerka (20 mg/kg) pri otrocih z epilepsijo (starih od 6 do 12 let) je bil razpolovni čas levetiracetama 6,0 ur.
With continued long-term treatment, 11.4% of the patients were seizure-free for at least 6 months and 7.2% were seizure-free for at least 1 year. 
Med nadaljevanjem dolgotrajnega zdravljenja je bilo 11,4 % bolnikov brez napadov vsaj 6 mesecev, 7,2 % pa jih je bilo brez napadov vsaj 1 leto.
Citric acid monohydrate Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Ammonium glycyrrhizate 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi natrijev citrat citronska kislina monohidrat metilparahidroksibenzoat (E218) propilparahidroksibenzoat (E216) amonijev glicirizat glicerin glicerol (E422)
Treatment with levetiracetam should be reviewed when a woman is planning to become pregnant. 
Če ženska načrtuje nosečnost, je treba ponovno pretehtati zdravljenje z levetiracetamom.
Pancreatitis 
Kreatinin
Specialist advice should be given to women who are of childbearing potential. 
Ženskam v rodni dobi mora svetovati zdravnik specialist.
A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1,800 mg/kg/day. 
Na podganah je bila opravljena študija peri- in postnatalnega razvoja z odmerki levetiracetama 70, 350
72.2% of the levetiracetam treated patients and 45.2% of the patients on placebo had a 50% or greater decrease in the frequency of PGTC seizures per week. 
Pogostnost PGTC-napadov na teden se je zmanjšala za 50 % ali več pri 72,2 % prejemnikov levetiracetama in pri 45,2 % prejemnikov placeba.
• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. 
• za zdravljenje miokloničnih napadov pri odraslih in mladostnikih od 12. leta starosti, ki imajo juvenilno mioklonično epilepsijo.
- A 300 ml bottle with a 3 ml oral syringe (delivering up to 300 mg levetiracetam) graduated every 0.1 ml (corresponding to 10 mg). 
- 300-ml steklenica s 3-ml peroralno brizgo (ki vsebuje do 300 mg levetiracetama) z odmernimi oznakami na 0,1 ml (to ustreza 10 mg).
58.3% of the levetiracetam treated patients and 23.3% of the patients on placebo had at least a 50% reduction in myoclonic seizure days per week. 
Vsaj 50 % zmanjšanje dni z miokloničnimi napadi na teden so ugotovili pri 58,3 % prejemnikov levetiracetama in pri 23,3 % prejemnikov placeba.
The active substance is called levetiracetam. 
Zdravilna učinkovina je levetiracetam.
300 ml oral solution with a 10 ml oral syringe. 
300 ml peroralne raztopine z 10-ml peroralno brizgo.
Immune system disorders 
MedDRA organski sistem
The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume. 
Ne levetiracetam ne njegov primarni presnovek nista pomembno vezana na beljakovine v plazmi (< 10 Volumen porazdelitve levetiracetama je približno 0,5 do 0,7 l/kg; ta vrednost je blizu celotni količini vode v telesu.
- A 300 ml bottle with a 1 ml oral syringe (delivering up to 100 mg levetiracetam) graduated every 0.05 ml (corresponding to 5 mg). 
- 300-ml steklenica z 1-ml peroralno brizgo (ki vsebuje do 100 mg levetiracetama) z odmernimi oznakami na 0,05 ml (to ustreza 5 mg).
How to take Levetiracetam Actavis Group 
Kako jemati zdravilo Levetiracetam Actavis Group
confusion, panic attack, emotional instability/mood swings, agitation; 
halucinacije, jeza, zmedenost, napad panike, čustvena nestabilnost/nihanja v razpoloženju, agitacija (motorični nemir)
The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established. 
Varnost in učinkovitost monoterapije z levetiracetamom pri otrocih in mladostnikih, mlajših od 16. let,
Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. 
Dopolnilno zdravljenje miokloničnih napadov pri odraslih in mladostnikih od 12. leta starosti z juvenilno mioklonično epilepsijo.
Use the 10 ml syringe included in the package. 
Uporabite 10-ml peroralno brizgo, priloženo v pakiranju.
Add-on therapy for infants from 1 month to less than 6 months 
Dodatno zdravilo za dojenčke od 1 meseca do manj kot 6 mesecev starosti
Bone marrow suppression was identified in some of the cases of pancytopenia. 
Supresija kostnega mozga je bila identificirana v nekaterih primerih pancitopenije.
With continued long-term treatment, 28.6% of the patients were free of myoclonic seizures for at least 6 months and 21.0% were free of myoclonic seizures for at least 1 year. 
Med nadaljevalnim dolgoročnim zdravljenjem je bilo brez miokloničnih napadov vsaj 6 mesecev 28,6 % bolnikov, vsaj 1 leto pa 21,0 % bolnikov.
Respiratory, thoracic and mediastinal disorders 
Bolezni dihal, prsnega koša in mediastinalnega prostora kašelj
If you forget to take Levetiracetam Actavis Group 
Če ste pozabili vzeti zdravilo Levetiracetam Actavis Group:
The possible side effects of an overdose of Levetiracetam Actavis Group are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma. 
V primerih prevelikega odmerjanja levetiracetama so opažali zaspanost, agitiranost, agresivnost, deprimirano raven zavesti, depresijo dihanja in komo.
Levetiracetam elimination is correlated to creatinine clearance. 
Očistek levetiracetama korelira z očistkom kreatinina.
Therefore a 50% reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60 ml/min/1.73 m2. 
< 60 ml/min/1,73 m2, je zato priporočljivo 50 % zmanjšanje dnevnega vzdrževalnega odmerka.
The other ingredients are: sodium citrate, citric acid monohydrate, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), ammonium glycyrrhizate, glycerin, glycerol (E422), maltitol liquid (E965), acesulfame potassium (E950), grape flavour (contains propylene glycol), purified water. 
(E218), propilparahidroksibenzoat (E216), amonijev glicirizat, glicerin, glicerol (E422), tekoči maltitol (E965), kalijev acesulfamat (E950), sroma grozdja (vsebuje propilenglikol), prečiščena voda.
Your doctor will prescribe the most appropriate pharmaceutical form of levetiracetam according to the age, weight and dose. 
Zdravnik bo glede na starost, telesno maso in odmerek predpisal najprimernejšo farmacevtsko obliko levetiracetama.
Safety results in paediatric patients in placebo-controlled clinical studies were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse reactions which were more common in children than in adults. 
Pri pediatričnih bolnikih so bili podatki o varnosti iz s placebom nadzorovanih študij skladni z varnostnim profilom levetiracetama pri odraslih.
Drug reaction with eosinophilia and systemic symptoms (DRESS), Hypersensitivity (including angioedema and anaphylaxis) 
Bolezni imunskega sistema reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS),
The renal clearance of levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration. 
To kaže, da se levetiracetam izloča z glomerularno filtracijo, ki ji sledi tubularna reabsorpcija, izločanje primarnega presnovka pa poleg glomerularne filtracije obsega še aktivno tubularno sekrecijo.
60 mg (0.6 ml) twice daily 
60 mg (0,6 ml) dvakrat na dan
For infants 1 month to less than 6 months, measure the appropriate dosage using the 1 ml syringe included in the package. 
Za dojenčke, stare od 1 meseca do manj kot 6 mesecev, ustrezen odmerek izmerite z uporabo
(2) Following dialysis, a 250 to 500 mg supplemental dose is recommended. 
(1) Prvi dan zdravljenja z levetiracetamom je priporočljiv polnilni odmerek 750 mg. (2) Po dializi je priporočljiv dodatni odmerek od 250 do 500 mg.
Tabulated list of adverse reactions 
(anafilaktične) reakcije
What Levetiracetam Actavis Group looks like and contents of the pack 
Izgled zdravila Levetiracetam Actavis Group in vsebina pakiranja
Pancytopenia, neutropenia, agranulocytosis 
driska, dispepsija, bruhanje, navzeja pankreatitis
250 to 750 mg twice daily 
250 do 750 mg dvakrat na dan
If you stop taking Levetiracetam Actavis Group 
Če ste prenehali jemati zdravilo Levetiracetam Actavis Group:
Excretion via faeces accounted for only 0.3% of the dose. 
V blatu se izloči le 0,3 % odmerka.
Levetiracetam Actavis Group 100 mg/ml oral solution contains maltitol liquid. 
Zdravilo Levetiracetam Actavis Group 100 mg/ml peroralna raztopina vsebuje tekoči maltitol.
Dose in children 6 months and older: 
Odmerek pri dojenčkih, starejših od 6 mesecev:
500 mg twice daily 
500 mg dvakrat na dan
Depression, hostility/ aggression, anxiety, insomnia, nervousness/irritability 
Psihiatrične motnje depresija, sovražnost/ agresivnost, anksioznost,
300 ml oral solution with a 3 ml oral syringe and an adaptor. 
300 ml peroralne raztopine s 3-ml peroralno brizgo in nastavkom
• cough; 
• kašelj
Maximum dose: 21 mg/kg twice daily 
Največji odmerek: 21 mg/kg dvakrat na dan
Levetiracetam Actavis Group oral solution includes methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). 
in propilparahidroksibenzoat (E216), ki lahko povzročita alergijske reakcije (lahko zapoznele).
0.85 ml twice daily 
0,85 ml dvakrat na dan
• abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea; 
• bolečina v trebuhu, driska, dispepsija (slaba prebava), bruhanje, slabost
If you get any side effects talk to your doctor or pharmacist. 
Če opazite kateri koli neželeni učinek, se posvetujte s svojim zdravnikom ali s farmacevtom.
The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. 
Neželeni učinki, o katerih so najpogosteje poročali, so nazofaringitis, somnolenca (zaspanost),
Infants 6 to 23 months, children and adolescents weighing less than 50 kg 
Odmerjanje pri otrocih, starih 6 mesecev in več, lažjih od 50 kg
500 to 1,000 mg twice daily 
500 do 1.000 mg dvakrat na dan
500 to 1,500 mg twice daily 
500 do 1.500 mg dvakrat na dan
Moderate 
Zmerno
Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses. 
vznemirjenost, agresivnost, poslabšanje pozornosti, zavrtje dihanja in koma.
Three presentations are available: - A 300 ml bottle with a 10 ml oral syringe (delivering up to 1,000 mg levetiracetam) graduated every 0.25 ml (corresponding to 25 mg). 
- 300-ml steklenica z 10-ml peroralno brizgo (ki vsebuje do 1.000 mg levetiracetama) z odmernimi oznakami na 0,25 ml (to ustreza 25 mg).
Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). 
Pri bolnikih, zdravljenih z antiepileptičnimi zdravili (vključno z levetiracetamom) so bili opisani samomor, poskus samomora, samomorilno razmišljanje in vedenje.
After measuring the correct dose with an appropriate syringe, Levetiracetam Actavis Group oral solution may be diluted in a glass of water or baby's bottle. 
Levetiracetam Actavis Group razredčite v kozarcu vode ali dojenčkovi steklenički.
100 mg (1 ml) twice daily 
100 mg (1 ml) dvakrat na dan
250 mg twice daily 
250 mg dvakrat na dan
Use the 3 ml oral syringe and adaptor included in the package 
Uporabite 3-ml peroralno brizgo in nastavek, priložena v pakiranju.
If you take more Levetiracetam Actavis Group than you should 
Če ste vzeli večji odmerek zdravila Levetiracetam Actavis Group, kot bi smel, se posvetujte z zdravnikom.
7 to 21 mg/kg (0.07 to 0.21 ml/kg) twice daily 
7 do 21 mg/kg (0,07 do 10 do 30 mg/kg (0,10 do 0,21 ml/kg) dvakrat na dan
No dose adjustment is needed in patients with mild to moderate hepatic impairment. 
Okvara jeter Bolnikom z blago do zmerno okvaro jeter odmerka ni treba prilagoditi.
300 ml oral solution with a 1 ml oral syringe and an adaptor. 
300 ml peroralne raztopine z 1-ml peroralno brizgo in nastavkom
300 ml amber glass bottle (type III) with a white child resistant closure (polypropylene) in a cardboard box also containing a 3 ml graduated oral syringe (polypropylene, polyethylene) and an adaptor for the syringe (polyethylene). 
300-ml steklenica (steklo tipa III) jantarne barve z belo, za otroke varno zaporko (polipropilen) v kartonski škatli, ki vsebuje tudi 3-ml peroralno brizgo z odmernimi oznakami (polipropilen, polietilen) in nastavek za brizgo (polietilen).
Levetiracetam Actavis Group 100 mg/ml oral solution Levetiracetam 
Levetiracetam Actavis Group 100 mg/ml peroralna raztopina levetiracetam
Contact your doctor if you have missed one or more doses. 
Če ste pozabili vzeti enega ali več odmerkov, se posvetujte z zdravnikom.
300 mg (3 ml) twice daily 
300 mg (3 ml) dvakrat na dan
Mild 
Hudo
(2) A 10.5 mg/kg (0.105 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam. 
(2) Prvi dan zdravljenja z levetiracetamom je priporočljiv polnilni odmerek 10,5 mg/kg (0,105 ml/kg).
300 ml amber glass bottle (type III) with a white child resistant closure (polypropylene) in a cardboard box also containing a 1 ml graduated oral syringe (polypropylene, polyethylene) and an adaptor for the syringe (polyethylene). 
300-ml steklenica (steklo tipa III) jantarne barve z belo, za otroke varno zaporko (polipropilen) v kartonski škatli, ki vsebuje tudi 1-ml peroralno brizgo z odmernimi oznakami (polipropilen, polietilen) in nastavek za brizgo (polietilen).
1.25 ml twice daily 
1,25 ml dvakrat na dan
300 ml amber glass bottle (type III) with a white child resistant closure (polypropylene) in a cardboard box also containing a 10 ml graduated oral syringe (polypropylene, polyethylene). 
300-ml steklenica (steklo tipa III) jantarne barve z belo, za otroke varno zaporko (polipropilen) v kartonski škatli, ki vsebuje tudi 10-ml peroralno brizgo z odmernimi oznakami (polipropilen, polietilen).
Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis). 
široko razširjen izpuščaj z mehurčki in luščenjem kože, še posebej okoli ust, nosu, oči in v predelu spolovil (Stevens-Johnsonov sindrom) in hujša oblika, ki povzroči luščenje kože na več kot 30 % telesne površine (toksična epidermalna nekroliza).
Metabolism and nutrition disorders 
Infekcijske in parazitske bolezni nazofaringitis okužba
(3) A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam. 
(3) Prvi dan zdravljenja z levetiracetamom je priporočljiv polnilni odmerek 15 mg/kg (0,15 mg/kg).
No adverse reactions on male or female fertility or reproduction performance were observed in rats at doses up to 1,800 mg/kg/day (x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation. 
Pri uporabi odmerkov do 1.800 mg/kg/dan (6-kratni največji priporočeni odmerek za človeka glede na mg/m2 ali izpostavljenost) pri podganah niso opazili neželenih učinkov na plodnost ali reprodukcijsko sposobnost samcev in samic ne pri starših in ne v generaciji F1.
Use the 1 ml syringe and adaptor included in the package. 
Uporabite 1-ml peroralno brizgo in nastavek, priložena v pakiranju.
250 to 500 mg twice daily 
250 do 500 mg dvakrat na dan
600 mg (6 ml) twice daily 
600 mg (6 ml) dvakrat na dan
7.5 ml twice daily 
7,5 ml dvakrat na dan
3.5 to 10.5 mg/kg (0.035 to 0.105 ml/kg) twice daily 
3,5 do 10,5 mg/kg (0,035 5 do 15 mg/kg (0,05 do do 0,105 ml/kg) dvakrat na dan
15 ml twice daily 
15 ml dvakrat na dan
0.35 ml twice daily 
0,35 ml dvakrat na dan
3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) twice daily 
3,5 do 7 mg/kg (0,035 do 5 do 10 mg/kg (0,05 do 0,07 ml/kg) dvakrat na dan
Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. 
(nevtropenija, agranulocitoza, levkopenija, trombocitopenija in pancitopenija) v povezavi z uporabo levetiracetama.
200 mg (2 ml) twice daily 
200 mg (2 ml) dvakrat na dan
0.6 ml twice daily 
0,6 ml dvakrat na dan
• depression, hostility or aggression, anxiety, insomnia, nervousness or irritability; 
• depresija, sovražnost ali agresivnost, tesnoba, nespečnost, živčnost ali razdražljivost • konvulzije, motnje ravnotežja, omotica (občutek nesigurnosti), letargija (pomanjkanje energije in navdušenja), tremor (nehoteno tresenje)
How to store Levetiracetam Actavis Group 
Shranjevanje zdravila Levetiracetam Actavis Group
0.8 ml twice daily 
0,8 ml dvakrat na dan
Levetiracetam Actavis Group 100 mg/ml oral solution is a clear, faint yellowish-brown solution. 
Zdravilo Levetiracetam Actavis Group 100 mg/ml peroralna raztopina je bistra, bledo rumenkastorjava raztopina.
Frequency category 
Pogostnost
44.6% of the levetiracetam treated patients and 19.6% of the patients on placebo had a 50% or greater reduction from baseline in the partial onset seizure frequency per week. 
Zmanjšanje tedenske pogostnosti napadov parcialnega izvora v primerjavi z izhodiščem za 50 % ali več je doseglo 44,6 % prejemnikov levetiracetama in 19,6 % prejemnikov placeba.
0.5 ml twice daily 
0,5 ml dvakrat na dan
1.8 ml twice daily 
1,8 ml dvakrat na dan